Beyond the dopamine receptor: novel therapeutic targets for treating schizophrenia
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
All current drugs approved to treat schizophrenia appear to exert their antipsychotic effects through blocking the dopamine D2 receptor. Recent meta-analyses and comparative efficacy studies indicate marginal differences in efficacy of newer atypical antipsychotics and the older drugs, and little effects on negative and cognitive symptoms. This review integrates findings from postmortem, imaging, and drug-challenge studies to elucidate a corticolimbic "pathologic circuit" in schizophrenia that may be particularly relevant to the negative symptoms and cognitive impairments of schizophrenia. Potential sites for pharmacologic intervention targeting glutatatergic, GABAergic, and cholinergic neurotransmission to treat these symptoms of schizophrenia are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Recent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904
Neurocognitive deficit in schizophrenia: A quantitative review of the evidence.
Heinrichs, R. W., & Zakzanis, K. K. (1998) · Neuropsychology · doi:10.1037/0894-4105.12.3.426 · Cited by 2,798
Cortical inhibitory neurons and schizophrenia
Lewis, D. A., Hashimoto, T., & Volk, D. W. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1648 · Cited by 2,297 · cited 1×
“More recent studies have revealed a much more selective effect primarily on the parvalbumin (PV)-expressing, fast-firing GABAergic interneurons in the intermediate layers of the cortex and in subsectors of the hippocampus that provide recurrent inhibition to the pyramidal cells.(34,35) Thus, the reduction in the expre…”
BackgroundDopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs
Creese, I., Burt, D. R., & Snyder, S. H. (1976) · Science · doi:10.1126/science.3854 · Cited by 2,220 · cited 1×
“Advances in ligand-binding techniques led Snyder and Seemen to demonstrate that there was a specific and highly robust correlation between the clinical potencies of antipsychotics and their ability to block the dopamine D2 receptor.(4,5) With the target of therapeutic action clearly identified, pharmacologists could t…”
BackgroundMoghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793
Decreased Dendritic Spine Density on Prefrontal Cortical Pyramidal Neurons in Schizophrenia
Glantz, L. A., & Lewis, D. A. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.1.65 · Cited by 1,636
Antipsychotic drug doses and neuroleptic/dopamine receptors
SEEMAN, P., LEE, T., CHAU-WONG, M., & WONG, K. (1976) · Nature · doi:10.1038/261717a0 · Cited by 1,622 · cited 1×
“Advances in ligand-binding techniques led Snyder and Seemen to demonstrate that there was a specific and highly robust correlation between the clinical potencies of antipsychotics and their ability to block the dopamine D2 receptor.(4,5) With the target of therapeutic action clearly identified, pharmacologists could t…”
BackgroundWhitfield-Gabrieli, S., Thermenos, H. W., Milanovic, S., Tsuang, M. T., Faraone, S. V., McCarley, R. W., Shenton, M. E., Green, A. I., Nieto-Castanon, A., LaViolette, P., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809141106 · Cited by 1,435 · cited 1×
“Disinhibition of glutamatergic output from the ventral hippocampus would drive the firing of dopaminergic neurons in the ventral tegmental area and enhanced subcortical dopamine release, which in PET studies correlates with psychosis.(50) Thus, in this model, psychosis is a downstream event.”
BackgroundAnis, N. A., Berry, S. C., Burton, N. R., & Lodge, D. (1983) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1983.tb11031.x · Cited by 1,399 · cited 1×
“Ketamine infused in normal volunteers at doses that do not cause delirium/dementia produced the full range of signs and symptoms of schizophrenia, with positive symptoms, negative symptoms, and the selective cognitive deficits.(27,28) Subsequent studies showed that low-dose ketamine caused in normal volunteers the phy…”
BackgroundThe glutamate homeostasis hypothesis of addiction
Kalivas, P. W. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2515 · Cited by 1,350
Nicotinic Acetylcholine Receptors and Nicotinic Cholinergic Mechanisms of the Central Nervous System
Dani, J. A., & Bertrand, D. (2007) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.47.120505.105214 · Cited by 1,197
Neurocognition in first-episode schizophrenia: a meta-analytic review.
Mesholam-Gately, R. I., Giuliano, A. J., Goff, K. P., Faraone, S. V., & Seidman, L. J. (2009) · Neuropsychology · doi:10.1037/a0014708 · Cited by 1,130
Shigemoto, R., Kinoshita, A., Wada, E., Nomura, S., Ohishi, H., Takada, M., Flor, P. J., Neki, A., Abe, T., Nakanishi, S., et al. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-19-07503.1997 · Cited by 1,116
Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders
Jeffrey Conn, P., Christopoulos, A., & Lindsley, C. W. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2760 · Cited by 1,063
Ressler, K. J., Rothbaum, B. O., Tannenbaum, L., Anderson, P., Graap, K., Zimand, E., Hodges, L., & Davis, M. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.11.1136 · Cited by 1,063 · cited 1×
“D-cycloserine has been effective in treating acrophobia in combination of a virtual reality-based cognitive behavioral therapy.(83,84) Thus, a key difference between the successful application of D-cycloserine in anxiety disorders and the unsuccessful application in schizophrenia may be that the in the former it is us…”
MethodPrevalence of smoking among psychiatric outpatients
(1986) · American Journal of Psychiatry · doi:10.1176/ajp.143.8.993 · Cited by 1,058
Allen, N. C., Bagade, S., McQueen, M. B., Ioannidis, J. P. A., Kavvoura, F. K., Khoury, M. J., Tanzi, R. E., & Bertram, L. (2008) · Nature Genetics · doi:10.1038/ng.171 · Cited by 1,054
Patil, S. T., Zhang, L., Martenyi, F., Lowe, S. L., Jackson, K. A., Andreev, B. V., Avedisova, A. S., Bardenstein, L. M., Gurovich, I. Y., Morozova, M. A., et al. (2007) · Nature Medicine · doi:10.1038/nm1632 · Cited by 1,040
Lisman, J. E., Coyle, J. T., Green, R. W., Javitt, D. C., Benes, F. M., Heckers, S., & Grace, A. A. (2008) · Trends in Neurosciences · doi:10.1016/j.tins.2008.02.005 · Cited by 1,010 · cited 1×
“NMDA receptors also play an important role in dendritic elaboration and spine development.(43) Mice that are homozygotes for a null mutation of serine racemase, the enzyme that synthesizes D-serine, exhibit marked reduction in NMDA receptor function.”
BackgroundSelf-citationStudy of a New Schizophrenomimetic Drug—Sernyl
LUBY, E. D. (1959) · Archives of Neurology And Psychiatry · doi:10.1001/archneurpsyc.1959.02340150095011 · Cited by 921
Glutamate and Schizophrenia: Beyond the Dopamine Hypothesis
Coyle, J. T. (2006) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-006-9062-8 · Cited by 917
Self-citationRegulation of Neurotransmitter Release by Metabotropic Glutamate Receptors
Cartmell, J., & Schoepp, D. D. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0750889.x · Cited by 883
Walker, D. L., Ressler, K. J., Lu, K.-T., & Davis, M. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-06-02343.2002 · Cited by 815 · cited 3×
“Studies employing cloned NMDA receptors expressed in a Xenopus oocyte system suggest the potency of D-serine is about three times that of glycine,72 and D-cycloserine is a partial agonist with only about half the efficacy of glycine at the GMS.73 Still, glycine and D-cycloserine have been more widely tested than D-ser…”
BackgroundWolosker, H., Blackshaw, S., & Snyder, S. H. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.23.13409 · Cited by 811
Synaptic mechanisms underlie nicotine-induced excitability of brain reward areas
Mansvelder, H. D., Keath, J. R., & McGehee, D. S. (2002) · Neuron · doi:10.1016/s0896-6273(02)00625-6 · Cited by 701
Schizophrenia, sensory gating, and nicotinic receptors
Adler, L. E., Olincy, A., Waldo, M., Harris, J. G., Griffith, J., Stevens, K., Flach, K., Nagamoto, H., Bickford, P., Leonard, S., et al. (1998) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033320 · Cited by 690
Freedman, R., Hall, M., Adler, L. E., & Leonard, S. (1995) · Biological Psychiatry · doi:10.1016/0006-3223(94)00252-x · Cited by 678
Klink, R., d'Exaerde, A. D. K., Zoli, M., & Changeux, J.-P. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-05-01452.2001 · Cited by 674
Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development
Wess, J., Eglen, R. M., & Gautam, D. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2379 · Cited by 637
Metabotropic glutamate receptors as novel targets for anxiety and stress disorders
Swanson, C. J., Bures, M., Johnson, M. P., Linden, A.-M., Monn, J. A., & Schoepp, D. D. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1630 · Cited by 607
Increased cortical kynurenate content in schizophrenia
Schwarcz, R., Rassoulpour, A., Wu, H.-Q., Medoff, D., Tamminga, C. A., & Roberts, R. C. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01078-2 · Cited by 590
Ketamine-Induced Loss of Phenotype of Fast-Spiking Interneurons Is Mediated by NADPH-Oxidase
Behrens, M. M., Ali, S. S., Dao, D. N., Lucero, J., Shekhtman, G., Quick, K. L., & Dugan, L. L. (2007) · Science · doi:10.1126/science.1148045 · Cited by 585 · cited 1×
“Several studies have demonstrated that subacute treatment of rats with dissociative anesthetics results in a downregulation of GAD67 and PV expression in the GABAergic neurons in the intermediate layers of the cortex and a consequent disinhibition of pyramidal neuronal firing.(40,41) This disinhibition of the pyramida…”
ResultBerk, M., Copolov, D., Dean, O., Lu, K., Jeavons, S., Schapkaitz, I., Anderson-Hunt, M., Judd, F., Katz, F., Katz, P., et al. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.03.004 · Cited by 552
A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy
Norberg, M. M., Krystal, J. H., & Tolin, D. F. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.01.012 · Cited by 510
GABA-based therapeutic approaches: GABAA receptor subtype functions
RUDOLPH, U., & MOHLER, H. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.10.003 · Cited by 499
Hashimoto, T., Bazmi, H. H., Mirnics, K., Wu, Q., Sampson, A. R., & Lewis, D. A. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07081223 · Cited by 457
Initial phase 2 trial of a nicotinic agonist in schizophrenia
Freedman, R., Olincy, A., Buchanan, R. W., Harris, J. G., Gold, J. M., Johnson, L., Allensworth, D., Guzman-Bonilla, A., Clement, B., Ball, M. P., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.07071135 · Cited by 426
Buchanan, R. W., Javitt, D. C., Marder, S. R., Schooler, N. R., Gold, J. M., McMahon, R. P., Heresco-Levy, U., & Carpenter, W. T. (2007) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.06081358 · Cited by 419
Cognitive Dysfunction in Schizophrenia: Convergence of γ-Aminobutyric Acid and Glutamate Alterations
Lewis, D. A., & Moghaddam, B. (2006) · Archives of Neurology · doi:10.1001/archneur.63.10.1372 · Cited by 404
Reduced Dendritic Spine Density in Auditory Cortex of Subjects with Schizophrenia
Sweet, R. A., Henteleff, R. A., Zhang, W., Sampson, A. R., & Lewis, D. A. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.67 · Cited by 290
Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders
Conn, P. J., Jones, C. K., & Lindsley, C. W. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.12.002 · Cited by 286
Krystal, J. H., Abi-Saab, W., Perry, E., D’Souza, D. C., Liu, N., Gueorguieva, R., McDougall, L., Hunsberger, T., Belger, A., Levine, L., et al. (2005) · Psychopharmacology · doi:10.1007/s00213-004-1982-8 · Cited by 272
Interleukin-6 Mediates the Increase in NADPH-Oxidase in the Ketamine Model of Schizophrenia
Behrens, M. M., Ali, S. S., & Dugan, L. L. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.4457-08.2008 · Cited by 241
Impaired attention is central to the cognitive deficits observed in alpha 7 deficient mice
Young, J. W., Crawford, N., Kelly, J. S., Kerr, L. E., Marston, H. M., Spratt, C., Finlayson, K., & Sharkey, J. (2007) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2006.03.008 · Cited by 233
Zhou, W., & Kalivas, P. W. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.06.008 · Cited by 225
Schizophrenia and the α7 Nicotinic Acetylcholine Receptor
Martin, L. F., & Freedman, R. (2007) · International Review of Neurobiology · doi:10.1016/s0074-7742(06)78008-4 · Cited by 213
Yee, B. K., Keist, R., von Boehmer, L., Studer, R., Benke, D., Hagenbuch, N., Dong, Y., Malenka, R. C., Fritschy, J.-M., Bluethmann, H., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508752102 · Cited by 201
Quartermain, D., Mower, J., Rafferty, M. F., Herting, R. L., & Lanthorn, T. H. (1994) · European Journal of Pharmacology · doi:10.1016/0014-2999(94)90687-4 · Cited by 190
Regulation of spine morphology and spine density by NMDA receptor signaling in vivo
Ultanir, S. K., Kim, J.-E., Hall, B. J., Deerinck, T., Ellisman, M., & Ghosh, A. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0704031104 · Cited by 187 · cited 1×
“Mice that are homozygotes for a null mutation of serine racemase, the enzyme that synthesizes D-serine, exhibit marked reduction in NMDA receptor function.(44) Cortical pyramidal neurons of these serine racemase knockout mice have significantly reduced dendritic complexity and spine density, as compared with their wil…”
The NMDA antagonist MK-801 blocks the extinction of Pavlovian fear conditioning.
Baker, J. D., & Azorlosa, J. L. (1996) · Behavioral Neuroscience · doi:10.1037/0735-7044.110.3.618 · Cited by 179
Laminar distribution of nicotinic receptor subtypes in cortical regions in schizophrenia
Marutle, A., Zhang, X., Court, J., Piggott, M., Johnson, M., Perry, R., Perry, E., & Nordberg, A. (2001) · Journal of Chemical Neuroanatomy · doi:10.1016/s0891-0618(01)00117-x · Cited by 175
Johnson, M. P., Barda, D., Britton, T. C., Emkey, R., Hornback, W. J., Jagdmann, G. E., McKinzie, D. L., Nisenbaum, E. S., Tizzano, J. P., & Schoepp, D. D. (2005) · Psychopharmacology · doi:10.1007/s00213-004-2099-9 · Cited by 156
Zhang, Y., Behrens, M. M., & Lisman, J. E. (2008) · Journal of Neurophysiology · doi:10.1152/jn.00079.2008 · Cited by 107
Dementia rating and nicotinic receptor expression in the prefrontal cortex in schizophrenia
Martin-Ruiz, C. M., Haroutunian, V. H., Long, P., Young, A. H., Davis, K. L., Perry, E. K., & Court, J. A. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00348-2 · Cited by 100
Role of GABAA receptors in cognition
Möhler, H. (2009) · Biochemical Society Transactions · doi:10.1042/bst0371328 · Cited by 79
Uptake of Radiolabeled Essential Amino Acids by Brain Following Arterial Injection
Oldendorf, W. H. (1971) · Experimental Biology and Medicine · doi:10.3181/00379727-136-35270 · Cited by 48
Cited by
NMDA Receptor and Schizophrenia: A Brief History
Coyle, J. T. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs076 · Cited by 410
Self-citationThe NMDA Receptor and Schizophrenia
Balu, D. T. (2016) · Advances in Pharmacology · doi:10.1016/bs.apha.2016.01.006 · Cited by 285
Self-citationDopamine Receptor Subtypes, Physiology and Pharmacology: New Ligands and Concepts in Schizophrenia
Martel, J. C., & Gatti McArthur, S. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01003 · Cited by 229
Nimgampalle, M., Chakravarthy, H., Sharma, S., Shree, S., Bhat, A. R., Pradeepkiran, J. A., & Devanathan, V. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101994 · Cited by 207
Glutamatergic Synaptic Dysregulation in Schizophrenia: Therapeutic Implications
Coyle, J. T., Basu, A., Benneyworth, M., Balu, D., & Konopaske, G. (2012) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-25758-2_10 · Cited by 180
“(Adapted from Coyle et al. 2010) Handb Exp Pharmacol.”
BackgroundSelf-citation
Metadata
- Authors
- Coyle, J. T., Balu, D., Benneyworth, M., Basu, A., & Roseman, A.
- Venue
- Dialogues in Clinical Neuroscience
- Publisher
- Informa UK Limited
- Published
- 2010-09-30
- Volume
- 12
- Issue
- 3
- Pages
- 359-382
- ISSN
- 1294-8322 (ISSN-L)
- 1958-5969
- OpenAlex
- W157021211
- Cited by
- 74
- References
- 58
- FWCI
- 5.58
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.